학술논문

Survival outcomes in ALK-positive NSCLC patients (p) treated 1st line brigatinib and impact of the ALK fusion variant
Document Type
Journal
Source
JOURNAL OF CLINICAL ONCOLOGY; JUN 1 2023, 41 16, 1p. Supplement: S
Subject
Language
English
ISSN
15277755